HCmed Signs a Global Development Agreement with Global Biotechnology Leader CSL Behring

b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).